 |
 |
 |
| |
Mikael Ørum,
Partner |
 |
 |
| |
Peter
Damsbo, MD,
Partner |
 |
 |
| |
Robert L. Buchanan , PhD,
Attorney at Law, Partner |
|
Martin Austin,
Partner
|
 |
 |
| |
Dede Willis, BSc, MBA,
Partner |
 |
 |
| |
Christina Wagner, PhD, Partner |
 |
 |
| |
Mirko
Stange, PhD,
Partner |
 |
 |
| |
Madeline
Yap, PhD,
Partner |
 |
 |
| |
Konstantinos Alevizopoulos, PhD, Partner |
 |
 |
| |
Spencer Ma MBA, FCPA, ACIS ,
Partner |
 |
 |
| |
Bengt Westrin, PhD, Assoc. Professor,
Partner |
 |
 |
| |
Pieter
Telleman, PhD, MBA,
Senior Advisor |
 |
 |
| |
Lars Hedbys,
M Sc, PhD,
Senior Advisor |
 |
 |
|
 |
| |
| |
|
|
Our Team
Dr. Christina Wagner | Partner
Dr. Christina Wagner joined Ventac Partners as a Partner in 2004. She is a corporate development, financing, and strategy expert for the Pharma and Biotech industry.
Dr. Christina Wagner is Chief Business Officer of Avexxin A/S and Advisor of Inveni Capital (www.invenicapital.com)
Prior to her engagement at Ventac Partners, Dr. Christina Wagner held a position as senior manager at MWG Biotech AG with responsibilities in turnaround, corporate strategy and collaboration development.
Before Dr. Christina Wagner was a consultant of the Boston Consulting Group. Here she was part of a number of high profiled client projects encompassing international strategy development, business planning, merger and acquisition for pharma, biotech and healthcare companies.
Dr. Wagner received her Ph.D in Chemical engineering from the Fraunhofer UMSICHT Oberhausen, Germany, in 1999. |
|

Christina Wagner, PhD
Partner |
|
|